Nagayama Takahiro, Zhang Manling, Hsu Steven, Takimoto Eiki, Kass David A
Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA.
J Pharmacol Exp Ther. 2008 Aug;326(2):380-7. doi: 10.1124/jpet.108.137422. Epub 2008 May 2.
Phosphodiesterase type 5 (PDE5) inhibitors are used to treat erectile dysfunction, and growing evidence supports potential cardiovascular utility. Their efficacy declines with reduced nitric-oxide synthase (NOS) activity common to various diseases. We tested whether direct soluble guanylate cyclase (sGC) stimulation restores in vivo cardiovascular modulation by PDE5 inhibition despite acute or chronically suppressed NOS activity. Mice (C57/Bl6; n = 62) were studied by in vivo pressure-volume analysis to assess acute modulation by the PDE5 inhibitor sildenafil (SIL; 100 microg/kg/min) of the cardiac response to isoproterenol (ISO) with or without NOS inhibition [N(omega)-nitro-L-arginine methyl ester (L-NAME)] and cotreatment by the sGC stimulator 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)pyrimidine-4,6-diamine (BAY 41-8543). SIL induced mild vasodilation but no basal cardiac effects and markedly blunted ISO-stimulated contractility. Acute BAY 41-8543 at a dose lacking cardiovascular effects did not alter ISO responses. However, after acute L-NAME, SIL ceased to influence cardiovascular function, but adding BAY 41-8543 fully restored SIL effects. After 1 week of L-NAME, neither SIL nor SIL + BAY 41-8543 acutely induced vasodilation or blunted ISO responses. However, sustained BAY 41-8543 despite concurrent NOS inhibition restored the cardiovascular efficacy of SIL. The disparity between acute and chronic NOS inhibition related to diffusion of PDE5 away from myocyte z-bands coupled with reduced protein kinase G activation. Both were restored by sustained sGC costimulation. Thus, PDE5 regulation of adrenergic reserve and systemic vasodilation depends upon NOS-induced cGMP/protein kinase G and can be enhanced by sustained low-level stimulation of sGC. This may prove beneficial for enhancing the efficacy of PDE5 inhibitors in conditions with chronically reduced NOS activity.
5型磷酸二酯酶(PDE5)抑制剂用于治疗勃起功能障碍,越来越多的证据支持其在心血管方面的潜在应用价值。在多种疾病中常见的一氧化氮合酶(NOS)活性降低会导致其疗效下降。我们测试了在急性或慢性抑制NOS活性的情况下,直接刺激可溶性鸟苷酸环化酶(sGC)是否能通过抑制PDE5来恢复体内心血管调节功能。通过体内压力-容积分析对小鼠(C57/Bl6;n = 62)进行研究,以评估PDE5抑制剂西地那非(SIL;100微克/千克/分钟)在有或无NOS抑制[N(ω)-硝基-L-精氨酸甲酯(L-NAME)]的情况下对心脏对异丙肾上腺素(ISO)反应的急性调节作用,以及与sGC刺激剂2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]-5-(4-吗啉基)嘧啶-4,6-二胺(BAY 41-8543)联合治疗的效果。SIL引起轻度血管舒张,但对基础心脏功能无影响,并显著减弱ISO刺激的收缩性。剂量对心血管功能无影响的急性BAY 41-8543不会改变ISO反应。然而,在急性给予L-NAME后,SIL不再影响心血管功能,但添加BAY 41-8543可完全恢复SIL的作用。在给予L-NAME 1周后,SIL或SIL + BAY 41-8543均未急性诱导血管舒张或减弱ISO反应。然而,尽管同时抑制NOS,但持续给予BAY 41-8543可恢复SIL的心血管疗效。急性和慢性NOS抑制之间的差异与PDE5从肌细胞z带扩散以及蛋白激酶G激活减少有关。通过持续的sGC共刺激,两者均得以恢复。因此,PDE5对肾上腺素能储备和全身血管舒张的调节取决于NOS诱导的cGMP/蛋白激酶G,并且可以通过持续低水平刺激sGC来增强。这可能对提高PDE5抑制剂在NOS活性长期降低的情况下的疗效有益。